Health Care [ 9/12 ] | Biotechnology [ 64/74 ]
NASDAQ | Common Stock
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.
It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage.
Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 25 | -0.19 Decreased by -105.83% | 0.11 Decreased by -272.73% |
| Feb 25, 25 | 1.98 Increased by +350.00% | 0.25 Increased by +692.00% |
| Nov 4, 24 | -0.54 Increased by +6.90% | -0.60 Increased by +10.00% |
| Aug 6, 24 | -0.50 Increased by +26.47% | -0.60 Increased by +16.67% |
| May 7, 24 | 3.26 Increased by +586.57% | 1.19 Increased by +173.95% |
| Feb 27, 24 | 0.44 Increased by +163.77% | -0.03 Increased by +1.57 K% |
| Nov 2, 23 | -0.58 Increased by +9.38% | -0.69 Increased by +15.94% |
| Aug 3, 23 | -0.68 Increased by +19.05% | -0.65 Decreased by -4.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 28.32 M Decreased by -88.89% | -11.65 M Decreased by -105.62% | Decreased by -41.15% Decreased by -150.60% |
| Dec 31, 24 | 170.64 M Increased by +184.40% | 131.67 M Increased by +381.70% | Increased by +77.17% Increased by +69.38% |
| Sep 30, 24 | 4.67 M Increased by +N/A% | -33.21 M Increased by +2.62% | Decreased by -710.37% Decreased by N/A% |
| Jun 30, 24 | 4.17 M Increased by +N/A% | -30.62 M Increased by +20.40% | Decreased by -734.73% Decreased by N/A% |
| Mar 31, 24 | 254.95 M Increased by +N/A% | 207.34 M Increased by +759.71% | Increased by +81.32% Decreased by N/A% |
| Dec 31, 23 | 60.00 M Increased by +N/A% | 27.34 M Increased by +187.37% | Increased by +45.56% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.10 M Decreased by -13.08% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -38.46 M Increased by +5.34% | Decreased by N/A% Decreased by N/A% |